HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.

AbstractPURPOSE:
Treatment of low-grade gastric mucosa-associated lymphoid tissue lymphoma by eradication of Helicobacter pylori is reported to result in complete lymphoma remission in approximately 75% of cases. The effect that cure of the infection has on the course of a primary high-grade gastric lymphoma is largely uncertain. The aim of this study was to report the effect of cure of H pylori infection exerted in patients with high-grade B-cell gastric lymphoma.
PATIENTS AND METHODS:
Eight patients (4 males and 4 females; age range, 26 to 85 years) with H pylori infection and high-grade lymphoma received eradication therapy before planned treatment. The effect of H pylori eradication on the course of high-grade lymphoma was assessed by analysis of surgical specimens (n = 2) or endoscopic biopsies (n = 6).
RESULTS:
H pylori eradication was successful in all patients and led to complete remission of the lymphoma in seven patients. One patient has experienced partial remission. Two patients were referred to surgery, one of whom (stage II(1E)) had lymph node involvement, and the histologic work-up of the resected stomach revealed residual infiltrates of a low-grade lymphoma, which prompted consolidation chemotherapy. In one patient (initially stage I(1E)), abdominal lymphoma developed 6 months after eradication therapy, which regressed completely after chemotherapy. In four patients, no further treatment was given. Six patients continue in complete remission (range, 6 to 66 months).
CONCLUSION:
Primary high-grade B-cell gastric lymphoma in stages I(E) through II(E1) associated with H pylori may regress completely after successful cure of the infection. Prospective trials are needed to investigate this treatment in larger numbers of patients.
AuthorsA Morgner, S Miehlke, W Fischbach, W Schmitt, H Müller-Hermelink, A Greiner, C Thiede, J Schetelig, A Neubauer, M Stolte, G Ehninger, E Bayerdörffer
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 19 Issue 7 Pg. 2041-8 (Apr 01 2001) ISSN: 0732-183X [Print] United States
PMID11283137 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Ulcer Agents
  • Penicillins
  • Amoxicillin
  • Omeprazole
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin (therapeutic use)
  • Anti-Ulcer Agents (therapeutic use)
  • Cell Transformation, Neoplastic
  • Female
  • Helicobacter Infections (complications, drug therapy)
  • Helicobacter pylori
  • Humans
  • Lymphoma, B-Cell (drug therapy, microbiology, pathology)
  • Lymphoma, B-Cell, Marginal Zone (drug therapy, microbiology, pathology)
  • Lymphoma, Non-Hodgkin (drug therapy, microbiology, pathology)
  • Male
  • Middle Aged
  • Omeprazole (therapeutic use)
  • Penicillins (therapeutic use)
  • Remission Induction (methods)
  • Retrospective Studies
  • Stomach Neoplasms (drug therapy, microbiology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: